Stoke Therapeutics Presents Data From Multiple Studies of Ch

– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support...

Related Keywords

United Kingdom , United States , Massachusetts , Bedford , Orlando , Florida , Cambridge , Cambridgeshire , American , Helen Cross , Joseph Sullivan , Barry Ticho , Archana Desurkar , Stoke Therapeutics Inc , American Epilepsy Society , Exchange Commission , Nasdaq , Pediatric Epilepsy Center , Augmentation Of Nuclear Gene Output , Company Annual Report On Form , International League Against Epilepsy , University Of California San Francisco , Stoke Therapeutics , Meeting December , Chief Medical Officer , California San Francisco , History Study , Dravet Syndrome Ages , Label Extension , Month Analysis , Observational Study , Investigate Cognition , Dravet Syndrome , Kingdom Investigating Safety , Drug Exposure , Antisense Oligonucleotide , Childhood Epilepsy , Developmental Neuroscience Programme , Child Health , Honorary Consultant , Paediatric Neurology , Open Label Extension , Previously Participated , Consultant Paediatric Neurologist , Sheffield Children , Hospital National Health Service Foundation Trust , Dosing Regimens , Senior Vice President , Clinical Pharmacology , Targeted Augmentation , Nuclear Gene Output , Private Securities Litigation Reform Act , Annual Report , Markets ,